NEW YORK (GenomeWeb) – German molecular diagnostics firm New Oncology today announced a collaboration with Gustave Roussy Cancer Campus in Paris to perform genetic testing to identify therapeutically relevant alterations in cancer-related genes.
New Oncology, the molecular diagnostics division of genomic analytics firm Blackfield, will use its proprietary diagnostic platform called Neo as part of the agreement. Neo allows rapid sample processing that is compatible with daily clinical routine and standard sample material such as formalin-fixed, paraffin-embedded tissue.
Financial and other details of the deal were not disclosed.
"The dramatic responses seen in patients receiving targeted treatment have shifted the therapeutic paradigm to therapies which are based on the molecular characteristics of a given cancer," Jean-Charles Soria, head of the drug development department at Gustave Roussy Cancer Campus, said in a statement. "Thus, comprehensive genomic diagnosis of FFPE tissues is an important step to optimize clinical care to patients throughout the different lines of therapy."
New Oncology is based in Cologne, Germany and has developed a next-generation-based test called NeoPlus, which analyzes a tumor and therapy-relevant target regions in a parallel multiplex manner, it said on its website. NeoPlus uses a computational biology platform to analyze sequencing data and identify mutations, amplifications, and rearrangements and verify their therapeutic relevance.